메드팩토, TEW-7197 미국 FDA 로부터 IND 승인
May 19, 2014EVENTSHit 1218
Korea National Cancer Center established National OncoVenture (NOV, Director: Dr. In-Chul Kim) for 10-year “Conquering Cancer” program in 2011 and this year NOV selected 2 anticancer drug candidates to support the non-clinical and clinical developments on Oct. 15th. MedPacto’s leading compound, TEW-7197, is one of them. It is a small molecule compound which is originally developed by Ewha Women’s University (Prof. Daekee Kim) supported by the Program for Disease-Based Discovery of Global New Drug Candidates. Its target indications are solid tumors. It is in-licensed from Ewha to MedPacto on Jul. 10th 2013.
- Tues 15 Oct. 2013 09:51 AM Republic of Korea
|Next||TEW-7197 임상 개시|
|Previous||메드팩토와 국립암센터 항암신약개발사업단(NOV), ALK5 저해제 TEW-7197 로 미국 FDA 에 IND 신청|